We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

AI Tool Uses Imaging Data to Detect Less Frequent GI Diseases

By LabMedica International staff writers
Posted on 05 Nov 2024
Print article
Image: LMU’s Professor Frederick Klauschen developed the novel approach that can improve diagnostic accuracy (Photo courtesy of LMU Munich)
Image: LMU’s Professor Frederick Klauschen developed the novel approach that can improve diagnostic accuracy (Photo courtesy of LMU Munich)

Artificial intelligence (AI) is already being utilized in various medical fields, demonstrating significant potential in aiding doctors in diagnosing diseases through imaging data. However, training AI models requires large datasets, which are typically abundant for common diseases. The real challenge lies in accurately detecting rarer diseases, which many current AI models tend to overlook or misclassify. Researchers have now created a new AI tool designed to utilize imaging data to identify less common gastrointestinal tract diseases effectively.

Developed by scientists at Ludwig Maximilian University of Munich (Munich, Germany) and their collaborators, this innovative model only requires training data from frequently observed conditions to reliably detect rarer diseases. This advancement has the potential to enhance diagnostic accuracy and alleviate the workloads of pathologists in the future. As reported in the New England Journal of Medicine AI (NEJM AI), the new technique is founded on anomaly detection. The model learns to identify and highlight deviations from the precise characterization of normal tissues and findings from common diseases, without the need for specific training on these less frequent cases. The researchers utilized a dataset of 17 million histological images from 5,423 cases for training and evaluation.

In their research, the team gathered two extensive datasets of microscopic images from gastrointestinal biopsy tissue sections, along with their corresponding diagnoses. In these datasets, the ten most common findings—including normal observations and prevalent diseases such as chronic gastritis—constituted approximately 90% of cases, while the remaining 10% encompassed 56 different disease entities, including various cancers. Additionally, the AI model employs heatmaps to visually indicate the location of anomalies within the tissue section. By distinguishing normal findings and common diseases while detecting anomalies, the AI model is poised to offer crucial support to healthcare professionals. Although the identified diseases still require validation by pathologists, this AI tool can significantly reduce diagnostic time, as it enables automatic diagnosis of normal findings and a portion of diseases.

“We compared various technical approaches and our best model detected with a high degree of reliability a broad range of rarer pathologies of the stomach and colon, including rare primary or metastasizing cancers. To our knowledge, no other published AI tool is capable of doing this,” said Professor Frederick Klauschen, Director of the Institute of Pathology at LMU.

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Sekisui Diagnostics UK Ltd.